Date: 2012-09-05
Type of information: Pipeline acquisition
Compound: preclinical antiviral programs including novel nucleotide polymerase inhibitors
Company: Medivir (Sweden) Novadex Pharmaceuticals (Sweden)
Therapeutic area: Infectious diseases
Type agreement: acquisition of preclinical research stage assets
Action mechanism:
Disease: hepatitis C
Details: Medivir, an emerging research-based pharmaceutical company focused on infectious diseases, has acquired preclinical research stage assets from Novadex Pharmaceuticals. The acquisition includes intellectual property and prodrug technologies in order to further strengthen Medivir’s hepatitis C platform and know how.
The acquired portfolio of research stage antiviral programs includes novel nucleotide polymerase inhibitors that have been identified and developed. It also includes prodrug technologies which could be applied to both protease inhibitors and nucleoside analogues to enhance their overall pharmacokinetic properties.
Financial terms: The transaction value, which consists of up-front payment as well as future potential milestone payments, is not disclosed.
Latest news:
